Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma

In 17 first-line patients treated with the combination, estimated two-year overall survival was 70%. Median overall survival had not been reached after a median follow-up of 29 months, and 10 patients remained on study; the small cohort limits how broadly these results can be interpreted.